149 related articles for article (PubMed ID: 38376651)
1. Preventing viral relapse with prophylactic tenofovir in hepatitis B carriers receiving chemotherapy: a phase IV randomized study in Taiwan.
Hsu CW; Chen SC; Wang PN; Wang HM; Chen YC; Yeh CT
Hepatol Int; 2024 Apr; 18(2):449-460. PubMed ID: 38376651
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Kim K; Kitrinos KM; Subramanian GM; McHutchison JG; Yee LJ; Elkhashab M; Berg T; Sporea I; Yurdaydin C; Husa P; Jablkowski MS; Gane E
J Hepatol; 2017 Jan; 66(1):11-18. PubMed ID: 27545497
[TBL] [Abstract][Full Text] [Related]
3. Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy.
Kuo MT; Tseng PL; Chou YP; Chang KC; Tsai MC; Kuo YH; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
J Gastroenterol Hepatol; 2018 Oct; 33(10):1766-1772. PubMed ID: 29514418
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL.
Tseng TN; Hu TH; Wang JH; Kuo YH; Hung CH; Lu SN; Jeng WJ; Chen CH
Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2803-2812.e2. PubMed ID: 32360818
[TBL] [Abstract][Full Text] [Related]
5. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
[TBL] [Abstract][Full Text] [Related]
6. Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy.
Chiu SM; Kuo YH; Wang JH; Hung CH; Hu TH; Lu SN; Chen CH
Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2989-2997.e3. PubMed ID: 32353534
[TBL] [Abstract][Full Text] [Related]
7. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
Berg T; Simon KG; Mauss S; Schott E; Heyne R; Klass DM; Eisenbach C; Welzel TM; Zachoval R; Felten G; Schulze-Zur-Wiesch J; Cornberg M; Op den Brouw ML; Jump B; Reiser H; Gallo L; Warger T; Petersen J;
J Hepatol; 2017 Nov; 67(5):918-924. PubMed ID: 28736139
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
[TBL] [Abstract][Full Text] [Related]
10. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial.
Iida-Ueno A; Enomoto M; Kozuka R; Tamori A; Kawada N
J Med Virol; 2019 Jul; 91(7):1295-1300. PubMed ID: 30815880
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial.
Segeral O; Dim B; Durier C; Nhoueng S; Chhim K; Sovann S; Yom S; Vong C; Yin S; Ros B; Ky V; Pech S; Nem B; Hout K; Guillebaud J; Ear E; Caroupaye-Caroupin L; Rekacewicz C; Fernandez L; Laurent D; Yay C; Kim R; Meyer L; Chhun S;
Lancet Infect Dis; 2022 Aug; 22(8):1181-1190. PubMed ID: 35643089
[TBL] [Abstract][Full Text] [Related]
12. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
[No Abstract] [Full Text] [Related]
13. Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen.
Jourdain G; Ngo-Giang-Huong N; Cressey TR; Hua L; Harrison L; Tierney C; Salvadori N; Decker L; Traisathit P; Sirirungsi W; Khamduang W; Bowonwatanuwong C; Puthanakit T; Siberry GK; Watts DH; Murphy TV; Achalapong J; Hongsiriwon S; Klinbuayaem V; Thongsawat S; Chung RT; Pol S; Chotivanich N
BMC Infect Dis; 2016 Aug; 16():393. PubMed ID: 27506549
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
15. A randomized open label trial of tenofovir monotherapy versus tenofovir plus telbivudine in spontaneous reactivation of hepatitis B.
Jindal A; Vyas A; Sharma M; Kumar G; Sarin SK
Saudi J Gastroenterol; 2019; 25(5):319-326. PubMed ID: 31044748
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study.
Wang T; Smith DA; Campbell C; Mokaya J; Freeman O; Salih H; McNaughton AL; Cripps S; Várnai KA; Noble T; Woods K; Collier J; Jeffery K; Davies J; Barnes E; Matthews PC
BMC Infect Dis; 2021 Jun; 21(1):610. PubMed ID: 34174833
[TBL] [Abstract][Full Text] [Related]
18. Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation.
Kuo YH; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
Hepatol Int; 2021 Apr; 15(2):301-309. PubMed ID: 33665773
[TBL] [Abstract][Full Text] [Related]
19. A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Kim DY; Kim YR; Suh C; Yoon DH; Yang DH; Park Y; Eom HS; Lee JO; Kwak JY; Kang HJ; Hyun SY; Jo JC; Chang MH; Yoo KH; Lim SN; Shin HJ; Kim WS; Kim IH; Kim MK; Kim HJ; Lee WS; Mun YC; Kim JS
Am J Gastroenterol; 2023 Aug; 118(8):1373-1380. PubMed ID: 36728217
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of telbivudine and tenofovir disoproxil fumarate in preventing hepatitis B vertical transmission: A real-life practice.
Liu J; Wang J; Yan T; Du D; Qi C; Cao F; Yao N; Yang Y; He Y; Tian Z; Ren D; Zhu L; Chen T; Zhao Y
J Viral Hepat; 2019 Oct; 26(10):1170-1177. PubMed ID: 31177596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
